Sandhya Girish Selected Research

polatuzumab vedotin

12/2020	Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
12/2020	Exposure-safety and exposure-efficacy analyses of polatuzumab vedotin in patients with relapsed or refractory diffuse large B-cell lymphoma.
1/2020	Asian race and origin have no clinically meaningful effects on polatuzumab vedotin pharmacokinetics in patients with relapsed/refractory B-cell non-Hodgkin lymphoma.
1/2020	Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
1/2020	Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sandhya Girish Research Topics

Disease

23	Breast Neoplasms (Breast Cancer) 04/2022 - 06/2010
18	Neoplasms (Cancer) 01/2022 - 02/2011
4	Body Weight (Weight, Body) 01/2021 - 05/2012
4	Non-Hodgkin Lymphoma (Lymphosarcoma) 12/2020 - 01/2020
4	Thrombocytopenia (Thrombopenia) 01/2015 - 06/2010
3	Stomach Neoplasms (Stomach Cancer) 01/2019 - 12/2017
2	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2020 - 12/2019
2	Chromosome Aberrations (Chromosome Abnormalities) 01/2020 - 12/2019
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2019 - 01/2018
2	Disease Progression 01/2019 - 01/2013
1	COVID-19 01/2021
1	Pathologic Complete Response 01/2021
1	Basal Cell Carcinoma (Rodent Ulcer) 01/2021
1	Melanoma (Melanoma, Malignant) 01/2021
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2020
1	Infections 01/2020
1	Lymphoid Leukemia 01/2020
1	Neutropenia 01/2020
1	Carcinoma (Carcinomatosis) 12/2019
1	Hematologic Neoplasms (Hematological Malignancy) 11/2019
1	Diarrhea 01/2019
1	Peripheral Nervous System Diseases (PNS Diseases) 01/2019
1	Brain Neoplasms (Brain Tumor) 08/2016
1	Anemia 06/2010
1	Fatigue 06/2010
1	Nausea 06/2010

Drug/Important Bio-Agent (IBA)

22	Ado-Trastuzumab EmtansineIBA 01/2019 - 06/2010
18	Immunoconjugates (Immunoconjugate)IBA 10/2020 - 06/2010
10	Trastuzumab (Herceptin)FDA Link 04/2022 - 02/2011
10	human ERBB2 proteinIBA 01/2019 - 02/2011
9	pertuzumabIBA 04/2022 - 10/2011
8	ErbB Receptors (EGF Receptor)IBA 01/2021 - 10/2011
5	polatuzumab vedotinIBA 12/2020 - 01/2020
4	Rituximab (Mabthera)FDA Link 12/2020 - 12/2019
3	AlbuminsIBA 01/2022 - 05/2012
3	atezolizumabIBA 12/2019 - 01/2018
3	Lapatinib (GW572016)FDA Link 04/2018 - 09/2012
3	Capecitabine (Xeloda)FDA Link 04/2018 - 09/2012
3	taxaneIBA 12/2017 - 09/2012
2	monomethyl auristatin EIBA 01/2020 - 01/2019
2	venetoclaxIBA 01/2020 - 12/2019
2	Transaminases (Aminotransferases)IBA 05/2012 - 06/2010
1	HhAntag691IBA 01/2021
1	TCVSIBA 01/2021
1	cobimetinibIBA 01/2021
1	VemurafenibIBA 01/2021
1	AntigensIBA 01/2021
1	DNA (Deoxyribonucleic Acid)IBA 01/2021
1	Peptides (Polypeptides)IBA 01/2021
1	Phosphotransferases (Kinase)IBA 01/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	Cancer VaccinesIBA 01/2021
1	Bendamustine Hydrochloride FDA Link 12/2020
1	obinutuzumabIBA 01/2020
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 01/2020
1	Prednisone (Sone)FDA LinkGeneric 01/2020
1	Doxorubicin (Adriamycin)FDA LinkGeneric 01/2020
1	CitrullineIBA 01/2019
1	Valine (L-Valine)FDA Link 01/2019
1	Estrogen ReceptorsIBA 10/2018
1	3- (4- (2- (2- chloro- 4- fluorophenyl)- 1- (1H- indazol- 5- yl)but- 1- en- 1- yl)phenyl)acrylic acidIBA 10/2018
1	Bevacizumab (Avastin)FDA Link 08/2016
1	AnthracyclinesIBA 09/2012
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 05/2012
1	Docetaxel (Taxotere)FDA Link 10/2011
1	Cytotoxins (Cytolysins)IBA 10/2011
1	Maytansine (Maitansine)IBA 10/2011
1	Sulfides (Thioethers)IBA 10/2011
1	Paclitaxel (Taxol)FDA LinkGeneric 10/2011
1	2- (1H- indazol- 4- yl)- 6- (4- methanesulfonylpiperazin- 1- ylmethyl)- 4- morpholin- 4- ylthieno(3,2- d)pyrimidineIBA 10/2011
1	Biological ProductsIBA 02/2011
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 02/2011
1	Pharmaceutical PreparationsIBA 06/2010

Therapy/Procedure

6	Therapeutics 01/2020 - 02/2011
4	Drug Therapy (Chemotherapy) 01/2019 - 02/2011
3	Immunotherapy 01/2022 - 01/2018
2	Subcutaneous Injections 04/2022 - 01/2021
1	Duration of Therapy 01/2019